Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

Table 1 Patient information

Patients	Age (mean, yr)	Sex (M/F)	Etiology (viral/non-viral)
Hepatitis	36.6	14/6	12/8
HCC	49.3	21/5	21/5
Total	43.8	35/11	33/13

HCC: Hepatocellular carcinoma.

Table 2 Characteristics of patient samples with hepatitis

No.	Age (yr)	Sex	Disease, etiology	HAI
LB10	35	M	Hepatitis, HBV	2
LB24	18	M	Hepatitis, HBV	2
LB18	43	M	Hepatitis, HBV	3
LB23	33	M	Hepatitis, HBV	3
LB26	36	F	Hepatitis, HBV	3
LB11	72	M	Hepatitis, HBV	4
LB21	40	M	Hepatitis, HBV	4
LB7	26	M	Hepatitis, HBV	4
LB9	40	F	Hepatitis, HBV	5
LB25	25	M	Hepatitis, HBV	6
LB31	28	M	Hepatitis, HBV	6
LB8	22	M	Hepatitis, HBV	13
LB4	36	F	Hepatitis	2
LB19	56	F	Hepatitis	2
LB22	28	F	Hepatitis	2
LB16	43	M	Hepatitis	3
LB20	42	F	Hepatitis	3
LB27	19	M	Hepatitis	3
LB30	55	M	Hepatitis	3
LB17	35	M	Hepatitis	4

HBV: Hepatitis B virus; HAI: Histological activity index.

Table 3 Characteristics of patient samples with hepatocellular carcinoma

No.	Sex	Age (yr)	Disease, etiology	Grade	Stage
c002	M	71	HCC, HBV	I	I
c005	M	42	HCC, HBV	I	I
c025	M	34	HCC, HBV	I	I
c009	M	58	HCC, HBV	I	IIb
c021	M	50	HCC, HBV	I	IIb
c042	M	48	HCC, HBV	I
c045	M	49	HCC, HBV	I
c014	M	48	HCC, HBV	II	I
c046	F	53	HCC, HBV	II
c023	F	34	HCC, HBV	III	IIa
c027	M	45	HCC, HBV	III	IIa
c026	F	18	HCC, HBV	III	IIb
c029	M	43	HCC, HBV	III	IIb
c043	M	61	HCC, HBV	III
c044	M	56	HCC, HBV	III
c020	M	49	HCC, HBV	IV	IIb
c040	M	52	HCC, HBV	IV
c004	M	64	HCC, HBV
c011	M	41	HCC, HBV
c019	F	40	HCC, HBV
c028	M	50	HCC, HBV
c015	M	48	HCC	I	I
c001	M	37	HCC	I	IIa
c003	M	62	HCC	I	IIa
c007	F	65	HCC	III	IIa
c022	M	64	HCC	IV	IIa

HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.

Table 4 Programmed death 1/programmed death ligands expression in liver tissues of patients with hepatitis (mean ± SD)

	n	PD-1	P	PD-L1	P	PD-L2	P
Age (yr)
< 36.6	12	1.67 ± 1.826	0.297	1.08 ± 1.240	0.873	1.83 ± 1.467	0.905
≥ 36.6	8	1.00 ± 0.926		1.00 ± 0.926		1.75 ± 1.581
Gender
Male	14	1.43 ± 1.604	0.903	1.07 ± 1.207	0.898	1.71 ± 1.437	0.702
Female	6	1.33 ± 1.506		1.00 ± 0.894		2.00 ± 1.673
ALT level (U/L)
Normal ( ≤ 40)	11	1.45 ± 1.440	0.866	1.27 ± 1.191	0.33	2.00 ± 1.673	0.517
Abnormal (> 40)	9	1.33 ± 1.732		0.78 ± 0.972		1.56 ± 1.236
TB level (μmol/L)
Normal ( ≤ 19)	13	1.46 ± 1.613	0.814	0.92 ± 0.862	0.496	1.77 ± 1.691	0.903
Abnormal (> 19)	7	1.29 ± 1.496		1.29 ± 1.496		1.86 ± 1.069
HAI score
< 4	12	1.00 ± 1.477	0.159	0.67 ± 0.778	0.053	1.50 ± 1.567	0.276
≥ 4	8	2.00 ± 1.512		1.62 ± 1.302		2.25 ± 1.282
Etiology
HBV	12	1.83 ± 1.528	0.125	1.42 ± 1.165	0.047	2.08 ± 1.311	0.304
Unknown	8	0.75 ± 1.389		0.50 ± 0.756		1.38 ± 1.685

PD: Programmed death; PD-L: Programmed death ligand; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; TB: Total bilirubin; HAI: Histological activity index.

Table 5 Programmed death 1/programmed death ligands expression in liver tissues of patients with hepatocellular carcinoma (mean ± SD)

	n	PD-1	P	PD-L1	P	PD-L2	P
Age (yr)
< 49.3	21	6.45 ± 4.510	0.397	4.56 ± 4.304	0.779	4.73 ± 3.524	0.202
≥ 49.3	5	4.90 ± 3.872		4.00 ± 3.625		2.80 ± 3.120
Gender
Male	21	5.60 ± 4.154	0.844	4.45 ± 4.390	0.826	3.67 ± 3.619	0.769
Female	5	6.00 ± 4.147		4.00 ± 3.098		4.17 ± 3.061
Stage
I	5	4.75 ± 2.500	0.252	7.50 ± 2.121	0.0181	2.75 ± 1.893	0.624
IIa	6	7.00 ± 5.612		1.75 ± 1.500		2.60 ± 2.302
IIb	5	1.67 ± 1.528		3.00 ± 0.001		1.33 ± 1.528
Grade
I, II	12	5.78 ± 3.632	0.958	6.80 ± 5.495	0.153	4.00 ± 3.775	0.736
III, IV	10	5.67 ± 4.975		2.44 ± 1.878		3.44 ± 3.046
Etiology
HBV	21	5.60 ± 4.154	0.844	4.69 ± 4.231	0.464	3.73 ± 3.615	0.876
Unknown	5	6.00 ± 4.147		3.00 ± 2.449		4.00 ± 3.098

¹The significance among different stages is mainly the difference between stage I and Stage II (including IIa and IIb) according to the SNK analysis. PD: Programmed death; PD-L: Programmed death ligand; HBV: Hepatitis B virus.

Table 6 Comparison of programmed death 1/programmed death-L expression in liver tissues of patients with hepatitis or hepatocellular carcinoma (mean ± SD)

Diagnosis	n	PD-1	P	PD-L1	P	PD-L2	P
Hepatitis	20	1.40 ± 1.536	0.000	1.05 ± 1.099	0.004	1.80 ± 1.473	0.020
HCC	26	5.71 ± 4.051		4.29 ± 3.885		3.81 ± 3.400

PD: Programmed death; PD-L: Programmed death ligand; HCC: Hepatocellular carcinoma.